X

Drug Profile

Anti-HM1-24 monoclonal antibody

Alternative Names: AHM

Latest Information Update: 12 Nov 2004

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chugai Pharmaceutical; University of Tokushima
Developer Chugai Pharma Europe
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma

Highest Development Phases

Discontinued Multiple myeloma

Most Recent Events

12 Nov 2004 Discontinued - Phase-I for Multiple myeloma in United Kingdom (Injection)
04 Nov 2002 Chugai Pharmaceutical has been acquired by Roche
10 May 2001 Anti-HM1-24 has received orphan drug status for multiple myeloma in the EU

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com